The Association Between the Risk of Breast Cancer and Epigallocatechin- 3-Gallate Intake: A Literature Review of a Potential Chemopreventive Agent.

Efstratios Athanasiou, Georgios-Ioannis Verras, Savvas Papageorgiou, Ioannis Kelesis, Athanasios Gatsis, Christina Karaoulani, Ioannis Stouras, Panagiotis Kanatas, Elmina-Marina Saitani, Maria-Eleni Oikonomou, Danae-Anastasia Vlassi, Maria Vasileiou, Christos Tsagkaris, Athanasios Alexiou, Mohammad Amjad Kamal

Journal: Current medicinal chemistry 2022;29(40):6169-6196

PMID: 35894455

Abstract

["According to the latest epidemiological data, breast cancer has recently been the most frequently diagnosed malignancy. To date, a body of evidence has established the involvement of multiple - and frequently interrelated - genetic and environmental factors in the pathogenesis of the disease. Emerging research on cancer prevention has highlighted the deterrence potential of interventions targeting environmental risk factors, particularly diet. In this aspect, the current review reveals the latest scientific results regarding epigallocatechin-3-gallate (EGCG) - a catechin most commonly found in green tea, as a potential chemopreventive dietary agent against breast cancer. in vitro studies on EGCG have demonstrated its effect on cell cycle progression and its potential to suppress several intracellular signaling pathways involved in breast cancer pathogenesis. In addition, EGCG possesses specific apoptosis-inducing characteristics that seem to enhance its role as a regulator of cell survival. Preclinical data seem to support using EGCG as an effective adjunct to EGFR-targeting treatments. The authors' appraisal of the literature suggests that although preclinical evidence has documented the anticarcinogenic features of EGCG, limited large-scale epidemiological studies are investigating the consumption of EGCG - containing nutrients in the prevention and management of breast cancer risk. This literature review aims to liaise between preclinical and epidemiological research, surveying the existing evidence and unraveling relevant knowledge gaps.",{"copyright":"Copyright\u00a9 Bentham Science Publishers; For any queries, please email at [email protected]."}]
Address: Department of Medicine, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece.; Cancer Prevention Research Group in Greece, Kifisias Avenue 44, Marousi, Greece.; Department of Surgery, General University Hospital of Patras, Patra, Greece.; Department of Molecular and Cell Biology, University of Leicester, Leicester, LEI 7RH, United Kingdom.; School of Medicine, Poznań University of Medical Sciences, Poznań, Poland.; Department of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.; Department of Obstetrics and Gynaecology, General Hospital of Florina, Florina, Greece.; Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece.; Novel Global Community Educational Foundation, Hebersham, NSW, Australia.; AFNP Med, Haidingergasse 29, Wien 1030, Austria.; Institutes for Systems Genetics, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China.; King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.; Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, Dhaka, Bangladesh.; Enzymoics, NSW; Novel Global Community Educational Foundation, Sydney, Australia.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.